ライフサイエンスコーパス: variable heavy chain

1 dues, whereas S1-15 utilizes exclusively the variable heavy chain.

2 The germline immunoglobulin (Ig) variable heavy chain 4-34 (VH4-34) gene segment encodes

3 ology (a mouse that expresses human antibody-variable heavy chains and kappa light chains) alongside

4 he complementarity-determining region of the variable heavy chain (CDRH1).

5 ragment (scFv) that consists of the antibody variable heavy chain connected to the variable light cha

6 eliminated by point mutation (Y100bP) in the variable heavy-chain domain to create an scFv (B6-2) tha

7 ert viral escape is the use of camelid VHHs (variable heavy chain domains of heavy chain antibody (al

8 ovement between the variable light chain and variable heavy chain domains within the antibody, but no

9 B cells of the largest Ig variable heavy chain gene (VH) family, VH3, are reported

10 malignant cells and unmutated immunoglobulin variable heavy chain gene have similarly been validated

11 Variable heavy chain gene usage was restricted, but simi

12 eting mAbs were restricted to expressing the variable heavy-chain gene VH3-23 with or without the var

13 s (N- to C-terminal) a pelB leader sequence, variable heavy chain, glycine-serine polylinker, variabl

14 alphaGal-containing N-linked glycan on a mAb variable heavy chain has potential clinical interest, as

15 displays somatically mutated immunoglobulin variable heavy chain (IgV(H)) genes, which suggests an o

16 adjacent to significant glycosylation of the variable heavy chain on asparagine 85 in Framework Regio

17 hain locus and 5'-flanking sequences of some variable heavy chain promoters.

18 ied ASCs punctuated by clones expressing the variable heavy-chain region VH4-34 that produced dominan

19 istal rearrangement of the gene encoding the variable heavy-chain region.

20 or post-GC phenotype and carrying mutated Ig variable heavy chain sequences.

21 the BCL-6 5'-noncoding region and in the Ig variable heavy chain sequences.

22 s, extensive somatic hypermutation and long, variable heavy-chain third complementarity-determining r

23 e presence or absence of immunoglobulin (Ig) variable heavy chain (V(H)) gene mutations.

24 ructed by diversifying a scaffold: the human variable heavy chain (V(H)) germ line gene 3-23, which w

25 that these anti-bodies display a restricted variable heavy chain (V(H)) repertoire and lack somatic

26 Immunoglobulin rearrangement from variable heavy chain (V(H)) to diversity (D)-joining hea

27 st position (Kabat numbering) in CDR3 of the variable heavy chain (V(H)), having aspartic acid (Asp)

28 tolerance using gene-targeted immunoglobulin variable heavy-chain (V(H)) alleles 3H9 or 56R, which en

29 Based on their variable heavy-chain (V(H)) gene usage, these antibodies

30 individual user-defined human immunoglobulin variable heavy-chain (V(H)) genes, including IGHV1-69, w

31 (referred to as Ig-Seq) and natively paired variable heavy chain-variable light chain high-throughpu

32 at positions S31R and W33T of the associated variable heavy chain (VH) allele were identified and con

33 3 antibody into an extensive matrix of human variable heavy chain (VH) and variable light chain (VL)

34 y fragments, consisting of an interconnected variable heavy chain (VH) and variable light chain (VL),

35 Variable heavy chain (VH) family frameworks (FWRs) have

36 y to interact with many members of an entire variable heavy chain (VH) or variable light chain gene f

37 fluids coupled to single-cell antibody gene (variable heavy chain [VH] and variable light chain [VL])

38 g enables the de novo generation of antibody variable heavy chains (VHHs), single-chain variable frag